Intervention: Vaccination

Wiedemann

France
|
2022
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Hospital
  • Outpatient clinic
  • Monkeypox virus
  • Mpox
  • Vaccination
  • MVA-BN

POQS-Boosted

Belgium
|
2026-2028
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Outpatient clinic
  • STD/STI clinic
  • Monkeypox virus
  • Mpox
  • Blood sample
  • Anorectal swab
  • Saliva sample
  • Vaccination
  • MVA-BN

Byrne

Ireland
|
2022-2024
  • Adults (18-64 years)
  • General population
  • Hospital
  • Monkeypox virus
  • Mpox
  • Blood sample
  • Vaccination
  • MVA-BN

Redjoul

France
|
2024-2024
  • Adults (18-64 years)
  • Elderly (≥65 years)
  • Fragile population
  • Immunocompromised host
  • Hospital
  • Respiratory syncytial virus
  • Respiratory syncytial virus infection
  • Pharmacological intervention
  • Vaccination

Havlin

Czech Republic
|
2024-2024
  • Adults (18-64 years)
  • Elderly (≥65 years)
  • Fragile population
  • Immunocompromised host
  • Hospital
  • Respiratory syncytial virus
  • Respiratory syncytial virus infection
  • Pharmacological intervention
  • Vaccination
  • Arexvy

SPIRAV

France
|
2025-2025
  • Adults (18-64 years)
  • Pregnant women
  • Hospital
  • Outpatient clinic
  • Respiratory syncytial virus
  • Respiratory syncytial virus infection
  • Pharmacological intervention
  • Monoclonal antibodies
  • Vaccination
  • Nirsevimab
  • Abrysvo

Drennan

United Kingdom
|
2022-2023
  • Adults (18-64 years)
  • People at high risk of STIs
  • STD/STI clinic
  • Monkeypox virus
  • Mpox
  • Sexually transmitted infection
  • Pharmacological intervention
  • Vaccination

Crandell

Portugal Brazil
|
2022-2023
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Outpatient clinic
  • Monkeypox virus
  • Mpox
  • Sexually transmitted infection
  • Blood sample
  • PBMC
  • Pharmacological intervention
  • Vaccination
  • MVA-BN
  • Dryvax

M-BOOST-FR

France
|
2025-2027
  • Adults (18-64 years)
  • Elderly (≥65 years)
  • People at high risk of STIs
  • Men who have sex with men
  • PrEP users
  • Outpatient clinic
  • Monkeypox virus
  • Mpox
  • Sexually transmitted infection
  • Serum
  • Pharmacological intervention
  • Vaccination
  • MVA-BN

VaQDENV

Italy
|
2024-2028
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Adolescents (12-17 years)
  • Children (1-11 years)
  • Outpatient clinic
  • Arbovirus
  • Dengue virus
  • Vector-borne disease
  • Arboviral disease
  • Vector-borne disease
  • Blood sample
  • Pharmacological intervention
  • Vaccination
  • Qdenga

STD-MAR/Mpox

Spain
|
2023
  • Adults (18-64 years)
  • People at high risk of STIs
  • PrEP users
  • People living with HIV
  • Hospital
  • Outpatient clinic
  • Monkeypox virus
  • Mpox
  • Blood sample
  • Pharmacological intervention
  • Vaccination
  • MVA-BN

REMAIN

Chile Panama Peru Spain
|
2022-2024
  • Adults (18-64 years)
  • People at high risk of STIs
  • Hospital
  • Outpatient clinic
  • Monkeypox virus
  • Mpox
  • Pharmacological intervention
  • Vaccination